


Fixed-duration treatment of 1st Line CLL with Acalabrutinib + Venetoclax: AMPLIFY-regimen now approved in Switzerland



Monday, November 24, 2025



18:00–19:00 CET



Location

FFHS Gleisarena, Zurich HB

Kopfbau, Zollstrasse 11, Room G11.404, 4th Floor, CH-8005 Zurich
Close to Zurich Main Station

AGENDA

18:00 – 18:05

Welcome & Introduction

Chair: Prof. Dr Davide Rossi

18:05 – 18:20

What's new in 1L CLL – the AMPLIFY study data

Prof. Dr Davide Rossi

18:20 – 18:35

From Guidelines to Practice: Integrating AMPLIFY into the New Onkopedia Guidelines

Prof. Dr Thorsten Zenz

18:35 – 18:55

From Data to Patients: Applying AMPLIFY in 1L CLL Treatment

Dr Young-Lan Song

18:55 – 19:00

Closing Remarks

Chair: Prof. Dr Davide Rossi

CHAIR



Prof. Dr Davide Rossi
IOSI Bellinzona

SPEAKERS



Prof. Dr Davide Rossi
IOSI Bellinzona



Prof. Dr Thorsten Zenz
USZ Zurich



Dr Young-Lan Song
Städtspital Triemli, Zurich



REGISTRATION

register@healthbook.ch

ORGANIZATION

H+O communications Ltd.
THE HEALTHBOOK COMPANY LTD.
Bundesplatz 14
CH 6300 Zug
Switzerland
www.hando.ch
www.healthbook.org